Medical Depot, Inc. v. Med Way US, Inc.

CourtDistrict Court, E.D. New York
DecidedApril 26, 2024
Docket2:22-cv-01272
StatusUnknown

This text of Medical Depot, Inc. v. Med Way US, Inc. (Medical Depot, Inc. v. Med Way US, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Medical Depot, Inc. v. Med Way US, Inc., (E.D.N.Y. 2024).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK ------------------------------------------------------------x MEDICAL DEPOT, INC. d/b/a DRIVE DEVILBISS HEALTHCARE,

Plaintiff, MEMORANDUM AND ORDER 2:22-cv-01272 (OEM) (SIL) v.

MED WAY US, INC., Defendant. ------------------------------------------------------------x

ORELIA E. MERCHANT, United States District Judge: Plaintiff Medical Depot, Inc. (“Plaintiff” or “Medical Depot”) filed the complaint in this action on March 8, 2022, against Defendant Med Way US, Inc. (“Defendant” or “Med Way”), bringing claims for trademark infringement, unfair competition, and cancellation of Defendant’s registered mark (“Registration No. 6,116,976”). Before the Court is Defendant’s motion in limine, filed on November 2, 2023, to (1) exclude certain portions of Jeremy N. Sheff’s (“Sheff”) expert report (the “Scheff Report”); (2) preclude Sheff from testifying on the excluded subjects; and (3) disqualify Sheff as an expert witness in the fields of consumer psychology and marketing. In its Memorandum of Law in Opposition (the “Opposition” or “Opp.”), Plaintiff argues that any exclusions made to Sheff’s report or testimony should correspondingly apply to Defendant’s expert, Francis Duffin. For the reasons that follow, Defendant’s motion in limine is granted. BACKGROUND Plaintiff and Defendant are both manufacturers of medical products, including specially designed medical air mattresses. See generally Complaint (“Compl.”), ECF 1. Plaintiff began selling various air mattress models using the descriptors “Med-Aire” and “Med Aire” in 2007. Compl. at 1. Plaintiff alleges that “[t]hrough Plaintiff’s exclusive and continuous use, the MED-AIRE mark has become synonymous with Plaintiff’s high-quality products and serves to identify Plaintiff as the sole source of these goods. Plaintiff’s MED-AIRE mark has become well-known by the general public and in relevant industries through widespread sales and advertising and promotion of the goods and services offered under the mark.” Id. at 2.

Plaintiff contends that its use of the terms “Med-Aire” and “Med Aire” since 2007 was substantial enough to merit trademark protections, while Defendant argues the opposite. Defendant claims that Plaintiff’s branding did not truly use “Med-Aire” or “Med Aire” as a product identifier, contending that the phrases were not placed in a special font, did not have a “TM” affixed afterward, were not used in a consistent and unaltered form, and did not create customer awareness of their trademarked usage. Defendant alleges that it began selling air mattress medical products using the name “MEDAIR” as early as April 1, 2019. Amended Answer, ECF 15 at 3. On December 10, 2019, Defendant filed United States Trademark Application Ser. No. 88/721,827, which matured into Registration No. 6,116,976, which covered use of the MEDAIR mark for International Class 10

medical products, namely “air mattresses with pump, for medical purposes.” Compl. at 6; see also Amended Answer at 3. At that time in 2019, Plaintiff’s “Med-Aire” phrase had not been registered with the USPTO. In 2020, Plaintiff sought to register the phrase “Med-Aire.” The USPTO initially refused registration due to Defendant’s competing “MEDAIR” trademark and because the provided specimen of trademark usage was deficient. After Plaintiff remedied its deficient specimen, the USPTO marked Plaintiff’s registration as “suspended” pending the outcome of legal action between the parties. PROCEDURAL HISTORY On March 8, 2022, Plaintiff filed the complaint in the instant action, arguing that Defendant’s use of the MEDAIR mark infringed on Plaintiff’s unregistered “Med-Aire” mark, which Plaintiff argues had gained trademark protection despite its lack of registration with the

USPTO. Plaintiff also brought claims for unfair competition and the cancellation of Registration No. 6,116,976. On May 5, 2022, Defendant filed its initial answer and counterclaim against Plaintiff, which was later amended on May 23, 2022. During the course of this action, Plaintiff retained Sheff to produce the Sheff Report and to provide testimony in regard to the subject matter of the Sheff Report if called to do so during pretrial proceedings. Sheff Report, ECF 58-1, at 3. Sheff is a tenured Professor of Law at St. John’s University School of Law, where he also serves as the Founding Faculty Director of the St. John’s Intellectual Property Law Center. Id. Sheff has taught Trademark Law and other courses at St. John’s University School of Law since 2008. Id. The Sheff Report purports to opine as to three issues:

The first is whether [Medical Depot]’s marketing and sales of products under its claimed MED-AIRE trademark establish “use in commerce” under the Lanham Act sufficient to establish priority of right as of July 13, 2018. This is the date currently claimed by Defendant Med Way US, Inc. (“Med Way”) as the date of its first use in commerce of the mark MEDAIR, used on or in connection with the goods and services “air mattresses with pump, for medical purposes” in International Class 10, which is the subject of United States Patent and Trademark Office (USPTO) Trademark Registration No. 6,116,976, Serial No. 88/721,827 (“the ‘976 Registration”). The second is whether the use by [Medical Depot] of its claimed MED-AIRE trademark on its products and associated sales materials constitutes “use as a mark” or “trademark use” under the Lanham Act as interpreted by the federal courts and the USPTO. The third is whether alternative presentations of [Medical Depot]’s claimed MED- AIRE trademark both with and without a hyphen and with or without an intervening space defeat its claim to priority.

Id. at 4. LEGAL STANDARD “Rule 702 of the Federal Rules of Evidence allows a ‘witness qualified as an expert by knowledge, skill, experience, training or education’ to testify if his ‘specialized knowledge will assist the trier of fact to understand the evidence or to determine a fact in issue.’” Cary Oil Co. v.

MG Ref. & Mktg., Inc., 2003 WL 1878246, at *1 (S.D.N.Y. Apr. 11, 2003) (quoting Fed. R. Civ. Pro. 702). “[T]he proponent of expert testimony has the burden of establishing by a preponderance of the evidence that the admissibility requirements of Rule 702 are satisfied.” U.S. v. Williams, 506 F.3d 151, 160 (2d Cir. 2007). This Court has wide latitude in determining whether the proponent of expert testimony has met this burden. See Patsy’s Italian Restaurant, Inc. v. Banas, 531 F. Supp. 2d 483, 484 (E.D.N.Y. 2008) (“It is well-settled that the determination of whether to admit expert testimony is within the sound discretion of the trial court.”). “One of the fundamental requirements of Rule 702 is that the proposed testimony ‘assist the trier of fact to understand the evidence or to determine a fact in issue.’” In re Rezulin Prods. Liab. Litig., 309 F. Supp. 2d 531, 540 (S.D.N.Y. 2004) (quoting Fed. R. Evid. 702). “For an

expert’s testimony to be admissible under this Rule, however, it must be directed to matters within the witness’ scientific, technical, or specialized knowledge and not to lay matters which a jury is capable of understanding and deciding without the expert’s help.” Andrews v. Metro N. Commuter R.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Williams
506 F.3d 151 (Second Circuit, 2007)
In Re Rezulin Products Liability Litigation
309 F. Supp. 2d 531 (S.D. New York, 2004)
Highland Capital Management, L.P. v. Schneider
551 F. Supp. 2d 173 (S.D. New York, 2008)
Patsy's Italian Restaurant, Inc. v. Banas
531 F. Supp. 2d 483 (E.D. New York, 2008)
In re Namenda Direct Purchaser Antitrust Litig.
331 F. Supp. 3d 152 (S.D. Illinois, 2018)
Scott v. Chipotle Mexican Grill, Inc.
315 F.R.D. 33 (S.D. New York, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
Medical Depot, Inc. v. Med Way US, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/medical-depot-inc-v-med-way-us-inc-nyed-2024.